Heart failure indication is broadened to highlight increased survival in patients with symptomatic heart failure. Approved April 8, the indication states that among these patients, Vasotec, usually in combination with diuretics and digitalis, "improves symptoms, increases survival and decreases the frequency of hospitalization." Previous labeling indicated Vasotec (enalapril) as an "adjunctive therapy in the management of heart failure." A supplemental NDA was submitted in August 1991. Among data supporting the revised indication are results from the NIH's SOLVD Treatment Trial showing that Vasotec "significantly reduced deaths in all stages of symptomatic heart failure" ("The Pink Sheet, Nov. 18, 1991, T&G-8).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth